€7.05
0.42% day before yesterday
Paris, Dec 27, 05:35 pm CET
ISIN
FR0012333284
Symbol
ABVX
Sector
Industry

Abivax SA Stock price

€7.05
-0.99 12.31% 1M
-5.01 41.54% 6M
-2.77 28.21% YTD
-2.87 28.93% 1Y
-20.75 74.64% 3Y
-16.15 69.61% 5Y
-13.95 66.43% 10Y
Paris, Closing price Fri, Dec 27 2024
-0.03 0.42%
ISIN
FR0012333284
Symbol
ABVX
Sector
Industry

Key metrics

Market capitalization €446.52m
Enterprise Value €323.40m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.51
Revenue (TTM) Revenue €0.00
EBIT (operating result TTM) EBIT €-179.27m
Free Cash Flow (TTM) Free Cash Flow €-154.77m
EPS (TTM) EPS €-3.28
P/E forward negative
P/S forward 69.79
EV/Sales forward 50.55
Show more

Is Abivax SA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Abivax SA Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Abivax SA forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Abivax SA forecast:

Buy
100%

Financial data from Abivax SA

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.95 0.95
164% 164%
-
-0.95 -0.95
164% 164%
-
- Selling and Administrative Expenses 42 42
271% 271%
-
- Research and Development Expense 135 135
107% 107%
-
-178 -178
131% 131%
-
- Depreciation and Amortization 0.95 0.95
164% 164%
-
EBIT (Operating Income) EBIT -179 -179
131% 131%
-
Net Profit -177 -177
92% 92%
-

In millions EUR.

Don't miss a Thing! We will send you all news about Abivax SA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development comprise of vaccine for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Head office France
CEO Marc Garidel
Employees 61
Founded 2013
Website www.abivax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today